Navigation Links
Combination of available tests helps predict Alzheimer's disease risk
Date:10/20/2011

With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older.

But even when early memory problems suggest the potential for impending AD, the actual risk is variable. Some patients are at high risk while others are not. The challenge for doctors has long been to differentiate that risk so they can determine the appropriate course of management.

In a paper to be published in the October 25 issue of the journal Neurology, a team of physicians and scientists from the University of California, San Diego School of Medicine and elsewhere describe using a combination of broadly available medical tests to produce a much improved predictive picture of the likelihood of impending AD in patients with mild cognitive impairment (MCI) an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia.

"I'm extremely excited about these results," said neurologist James Brewer, MD, PhD, an associate professor of radiology and neurosciences and part of the Alzheimer's Disease Neuroimaging Initiative research team at UC San Diego. "The good news is that we can partially reassure those folks who are negative on these tests, at least regarding their next three years. We have never been able to do that before. These individuals, despite having a real memory problem, have no greater risk of near-term dementia than a similarly aged healthy person without a memory complaint."

To determine the likelihood of developing Alzheimer's disease, the UC San Diego researchers compared risk factors based on magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) and neuropsychological testing. Unlike other efforts that have evaluated the predictive capabilities of research-based biomarkers, MRI, CSF and neuropsychological tests are all technologies widely available to clinicians.

The researchers found that these available biomarkers significantly improved accuracy in predicting near-term conversion to dementia. In combination, their prediction rate was almost perfect: None of the individuals who tested negative on all three measures went on to develop AD in the three-year follow-up. By comparison, almost 90 percent of individuals who tested positive on all three measures were demented at the end of three years.

The presence of medial temporal atrophy, determined by automated analysis of MRI using an FDA-approved software package, was associated with the likeliest chance of near-term dementia, with a median dementia-free survival time of only 15 months.

Brewer said the findings foretell a paradigm shift in the diagnosis of Alzheimer's disease.

"Instead of saying, 'Let's wait a year and see if this gets worse,' our neurologists can say, 'Let's get a volumetric MRI and check back in a month to see if your complaint is due to neurodegeneration.' That ability makes a huge difference in how we proceed. Maybe the memory complaint isn't due to neurodegeneration, but rather it's a side effect of a medication, a sign of depression or someone is simply anxious and worried. Being able to reassure at least some patients that they are not at significant near-term risk of AD is something we never could do in the past, given the high prevalence of the disease."


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Combination therapies for drug-resistant cancers
2. Combination therapy beneficial for head and neck skin carcinomas, UNC study shows
3. Phase II study shows new cancer drug combination significantly delays breast cancer progression
4. Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
5. Combination therapy rids common infection from implanted medical devices
6. Metformin and exercise combination less effective for glucose control
7. Combination of existing safety checks could greatly reduce radiotherapy errors
8. Hypnosis/local anesthesia combination during surgery helps patients, reduces hospital stays
9. Combination antibody therapy shows promise in metastatic melanoma
10. Combination therapy shows promise for rare, deadly cancer caused by asbestos
11. Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: